Corticosteroid injection and prolotherapy with dextrose may be brought up for discussion when there is chronic musculoskeletal pain, but they are not treatments that can be used in place of each other. A suitable comparison depends on the diagnosis, the position, the target tissue, previous treatment, and the goals, not merely on which method is described as stronger or as lasting longer.

Corticosteroids have a clearly known anti-inflammatory action and have evidence for some states. Prolotherapy has the purpose of creating a biological stimulus at a particular place, but the evidence of benefit is still inconsistent, and it has not yet been confirmed that it can repair and build ligaments or tendons. Neither method is an answer that guarantees a result for chronic pain.

The same symptoms may require different decisions

Pain near a joint or a tendon may come from joint degeneration, inflammatory arthritis, inflamed bursa, a state of abnormality of the tendon, an acute or chronic tendon tear, a fracture, infection, an irritated nerve, or pain referred from another position. Several factors may arise together, and the level of pain does not directly tell the damage to the tissue.

Before discussing injection, the doctor should determine the preliminary diagnosis, screen for urgent causes, and explain whether the target is a joint, a bursa, a tendon sheath, the tissue beside a tendon, a ligament, or another structure.

Corticosteroid injection: which cases does the evidence suit

Corticosteroids reduce the signals of inflammation, may relieve the symptoms in inflammatory states or in some joint diseases, and sometimes help open a short period in which rehabilitation can be done more comfortably.

For degenerative joint disease, NICE (opens in a new tab) advises that corticosteroid injection into the joint may be considered when other medicines have not worked or are not suitable, or in order to support therapeutic exercise. The relief expected is short-term, about 2–10 weeks, and the guideline found no evidence of benefit beyond 3 months. This figure is information specific to the guideline on degenerative joint disease and should not be applied to every position.

The evidence for tendon disease also depends on the diagnosis. A review of 41 trials with 2,672 participants (opens in a new tab) found short-term benefit in some states of the tendon, but for the tendon at the lateral side of the elbow, the results in the medium and long term favoured other treatments. The researchers warned that the results should not be generalised across tendon positions.

Therefore, steroid injection is not always a dangerous method, nor a long-term strategy that can be used in every case. The indication, the exact position, the alternatives, previous injections, and the activity planned are all important.

Prolotherapy: the proposed mechanism and the evidence that is still uncertain

Prolotherapy usually uses dextrose at high concentration injected at or near a selected structure. There is a hypothesis that the osmotic and inflammatory stimulus may have an effect on the signals of repair at that particular place. Laboratory mechanisms concerning inflammatory mediators, fibroblasts, and collagen processes are not evidence that new structure is created in patients.

A systematic review and meta-analysis of 2020 (opens in a new tab) included 10 trials with 358 participants who had states of the tendon, the plantar fascia, or ligament injury, and found that the evidence is still not enough to support a clinical benefit overall.

A review of 2024 (opens in a new tab) included 20 randomised trials with 1,136 participants who had tendon states from sport, and reported results for pain or function that are of interest in some diseases, but the kinds of disease and the methods of treatment differ, and larger comparative trials are still needed.

This information supports an informed discussion separated by disease, but does not support a guarantee that prolotherapy makes tissue strong, puts right an unstable joint, or gives a better long-term result than corticosteroid injection.

No method wins in every case

The decision is not merely "reducing inflammation" against "repairing tissue". Corticosteroids may reduce the symptoms without putting right every factor of the pain, while prolotherapy has a proposed mechanism in the direction of repair, but the clinical evidence does not yet confirm repair or superiority in every disease.

In some diagnoses, neither kind of injection may be the suitable next step. Education, adjusting activity, graded exercise, medicines, walking aids or aids for working, or an assessment for surgery may have better evidence. Direct comparative evidence is still not enough to rank one method as better in general.

The assessment and ultrasound guidance

The history, the examination, functional tests, and imaging where there is an indication should support the diagnosis. Ultrasound helps in seeing soft tissue or targets within certain joints and increases the precision of needle placement, but it cannot identify the root cause of the pain in every case or guarantee a response.

The EULAR recommendations for intra-articular injection (opens in a new tab) state that informed consent should be obtained, an aseptic technique used, and image guidance considered where available in order to increase precision. The substance, the dose, the method, and the target injected should be recorded.

The risks and the precautions

Both procedures may cause pain, bruising, bleeding, infection, an allergic reaction to the substance, or injury to nerves, blood vessels, or neighbouring tissue. The risks depend on the target, the substance, the technique, the person carrying out the procedure, and the health factors of the individual.

Corticosteroids may cause a temporary flare-up of pain, changes to the skin or the fat beneath it, facial flushing, and temporarily high blood sugar. EULAR advises that those with diabetes, particularly those whose control is not good, should monitor their sugar level with special care in the first 1–3 days after intra-articular glucocorticoid injection. Repeated injection should be a shared decision according to the result of the previous one and the risks of the individual, not automatically scheduled again.

Prolotherapy may cause a flare-up of pain after the injection, and the safety data is still less in many diseases and many methods. The doctor should review the risk of infection, the history of drug allergy, pregnancy where relevant, the risk of bleeding, the medicines used, and implanted devices in the body as suitable. Anticoagulants or medicines prescribed by a doctor should not be stopped without advice from the prescriber.

Rehabilitation and following up the result

Injection does not take the place of rehabilitation. The plan may cover gradually increasing the load, strength, mobility, the control of movement, balance, walking, and returning to work or to sport. The programme should match the diagnosis and the response, not be a standard set of treatment after injection.

It should be agreed in advance which outcomes are important, such as pain, sleep, walking distance, the ability to work, strength, or other functions, and when the reassessment will be. Treatment that does not achieve the goals should not be continued automatically.

Questions before choosing an injection

  1. What is the preliminary diagnosis, and what supports it?
  2. Which structure will be injected, and is the target inside or outside the joint?
  3. What evidence matches this disease and this position?
  4. What benefit, length of time, and uncertainty should be expected?
  5. Which substance, dose, and technique will be used?
  6. Will ultrasound guidance increase the precision for this target?
  7. What are the risks, the alternatives, the total costs, and the rehabilitation plan?
  8. When will the result be assessed, and what are the criteria for stopping?

Frequently asked questions

Is prolotherapy better than corticosteroid injection?

There is no such conclusion in general. The evidence, the benefit expected, and the risks differ according to the disease and the position. Some states have better evidence for corticosteroids, while the evidence for prolotherapy is still uncertain and diverse.

Does corticosteroid injection repair tissue?

Its main purpose is to reduce inflammation and the symptoms; it does not aim to create tendon anew, although short-term relief of pain may help the patient take part in rehabilitation.

Does prolotherapy repair tissue?

There is not yet evidence to confirm it. The proposed biological mechanism is not the same as structural repair or confirmed long-term function.

Does ultrasound guidance make an injection work?

No. Ultrasound may help in seeing structures and placing the needle more precisely in suitable targets, but it does not confirm the diagnosis or guarantee a benefit.

When should urgent care be received

An urgent assessment should be received when there is a severe injury, deformity, sudden loss of strength or function, being unable to bear weight, a hot swollen joint, fever, spreading redness, or new neurological symptoms. After an injection, medical advice should be sought quickly if the pain increases severely, there is fever, discharge, new weakness or numbness, difficulty breathing, or an unexpected reaction